危重症患者β-内酰胺类抗生素治疗药物监测:直接测定游离药物浓度以实现适当药物暴露
在单中心前瞻性TDM项目中,直接测定330例危重症患者7种β-内酰胺类抗生素的游离浓度,评估PK/PD目标达成情况及失败因素。33.1%和63.4%的病例需增加剂量才能达到100% fT>MIC和100% fT>4×MIC,17.3%的病例因超过100% fT>10×MIC需减量;高蛋白结合药物目标达成更好但易过量,ARC增加达标失败风险。PK/PD结果与临床结局无相关性,其临床意义未知。
要点
- 33.1%和63.4%的病例需增加剂量才能达到100% fT>MIC和100% fT>4×MIC目标。
- 17.3%的病例因超过100% fT>10×MIC上限阈值需减少剂量。
- 高蛋白结合β-内酰胺类目标达成更好但易过量;ARC增加达标失败风险(OR 2.47和3.05)。
核心结论
- 作为常规TDM项目的一部分,测定β-内酰胺类游离浓度是可行的,且表明大量危重症患者未达到预设PK/PD目标。
- 由于PK/PD结果与临床结局之间缺乏相关性,该发现的临床意义未知。
研究设计与样本
- 单中心前瞻性研究,获取血浆样本和临床数据进行分析。
- 采用超速离心法直接测定头孢曲松、头孢唑林、美罗培南、氨苄西林、青霉素G、氟氯西林和哌拉西林的游离浓度。
- 纳入330例患者的TDM数据和369次感染发作。
- 采用二项逻辑回归评估与PK/PD目标达成或不良临床结局相关的因素。
主要发现
- 给药剂量范围为相对于标准日剂量的99.4% ± 45.1%。
- 33.1%的病例需增加剂量以达到100% fT>MIC目标,63.4%的病例需增加剂量以达到100% fT>4×MIC目标。
- 17.3%的病例因超过100% fT>10×MIC的上限PK/PD阈值需减少剂量。
- 蛋白结合率较高的β-内酰胺类(头孢曲松和青霉素G)治疗目标达成更好(P < 0.01),但易发生过剂量。
- Augmented renal clearance(计算CLCR >130 mL/min)增加未达到100% fT>MIC和100% fT>4×MIC的比值比(OR分别为2.47和3.05;P < 0.01)。
关键数值与推荐
- PK/PD目标包括100% fT>MIC、100% fT>4×MIC和上限阈值100% fT>10×MIC。
- Augmented renal clearance定义为计算CLCR >130 mL/min。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To describe the achievement of unbound β-lactam antibiotic concentration targets in a therapeutic drug monitoring (TDM) programme in critically ill patients, and the factors associated with failure to achieve a target concentration. PATIENTS AND METHODS: Plasma samples and clinical data were obtained for analysis from a single centre prospectively. Unbound concentrations of ceftriaxone, cefazolin, meropenem, ampicillin, benzylpenicillin, flucloxacillin and piperacillin were directly measured using ultracentrifugation. Factors associated with the achievement of pharmacokinetic/pharmacodynamic (PK/PD) targets or negative clinical outcomes were evaluated with binomial logistic regression. RESULTS: TDM data from 330 patients, and 369 infection episodes, were included. The range of doses administered was 99.4% ± 45.1% relative to a standard daily dose. Dose increases were indicated in 33.1% and 63.4% of cases to achieve PK/PD targets of 100% fT>MIC and 100% fT>4×MIC, respectively. Dose reduction was indicated in 17.3% of cases for an upper PK/PD threshold of 100% fT>10×MIC. Higher protein bound β-lactams (ceftriaxone and benzylpenicillin) had better therapeutic target attainment (P < 0.01), but were prone to excessive dosing. Augmented renal clearance (calculated CLCR >130 mL/min) increased the odds of failure to achieve 100% fT>MIC and 100% fT>4×MIC (OR 2.47 and 3.05, respectively; P < 0.01). CONCLUSIONS: Measuring unbound concentrations of β-lactams as part of a routine TDM programme is feasible and demonstrates that a large number of critically ill patients do not achieve predefined PK/PD targets. The clinical significance of this finding is unknown due to the lack of correlation between PK/PD findings and clinical outcomes.
引用
- Wong G, Briscoe S, McWhinney B, et al. Therapeutic drug monitoring of β-lactam antibiotics in the critically ill: direct measurement of unbound drug concentrations to achieve appropriate drug exposures. J Antimicrob Chemother. 2018. PMID: 30137377. doi:10.1093/jac/dky314
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。